Harrow (HROW): The Conversion Test Behind A Leveraged Eye-Care Pivot

Harrow is a Nashville based ophthalmic pharmaceutical company that markets FDA approved branded products alongside a sizable compounded portfolio sold under the ImprimisRx name. The branded shelf now spans the front and back of the eye: VEVYE in dry eye disease, IHEEZO as the leading ophthalmic surface anesthetic gel, TRIESENCE as an injectable ocular steroid, BYOOVIZ as the first approved biosimilar referencing Lucentis, and a bench of specialty brands covering vernal keratoconjunctivitis, fungal keratitis and pressure control. Revenue in fiscal 2025 reached $272.3 million, a full third above the prior year, and that growth came overwhelmingly from the branded transition rather than from compounding. The prior year printed $199.6 million, so the step change tracks the acquisition cycle rather than any standing business. The pattern matters because acquired launch curves dominate the model, and launch curves grade on execution again every year.

The pivot that defines the current setup is deliberate substitution of a compounding business for an owned branded portfolio. Project Beagle, a continuity of care program announced in March 2025, walks roughly 25,000 patients off the Klarity compounded cyclosporine formula and onto VEVYE. PharmaPack, launched in February 2026, gives prescribers a direct cash channel for approved alternatives. Both moves trade low friction legacy revenue for higher value product revenue that the company owns outright. The cost of that migration shows up plainly in the ImprimisRx line, which fell to $14.6 million in the second quarter from $21.5 million a year earlier, a decline management attributes largely to design rather than to demand destruction. The accounting reads oddly in isolation, yet the mechanism is plain, since a patient moved from a compounded formula to the branded equivalent keeps the therapy relationship and raises the revenue captured per script.

Capital allocation has carried the pivot. In September 2025 the company refinanced its entire prior debt stack with senior unsecured notes at eight and five eighths percent, a $250 million issue that matures at the decade's end. Another $50 million of the same paper followed in March 2026. The proceeds funded a run of asset acquisitions: the Santen portfolio including VEVYE, TRIESENCE and NATACYN, the Samsung Bioepis biosimilar license that brought BYOOVIZ to market, and the Melt Pharmaceuticals acquisition closed in November 2025 that delivered the MELT sedation platform. Each deal added either revenue, margin, or pipeline, and each added either amortization, coupons, or both. The balance sheet effect is visible in stockholders equity, which compressed to roughly $15 million at midyear from $52 million six months earlier. Equity that thin leaves the notes as the effective owners of the enterprise in any downside, and the common shares price that reality once the coupon eats the cushion.

The strategic context for 2026 therefore reads less like a turnaround and more like a leveraged re underwriting of the same franchise. Management has told shareholders the company targets a $250 million revenue quarter by the end of 2027, an annualized pace near a billion. Full-year guidance calls for revenue inside the band from $350 million to $365 million. Adjusted EBITDA guidance spans $80 million to $100 million on the same frame. Certainty belongs to no one here; the portfolio breadth is real, and so is the coupon. The question the market prices between now and the fourth quarter is whether demand conversion shows up in the reported lines fast enough to service the paper that bought it. That question has compressed into a matter of weeks, because the guidance placed nearly every proof point inside a single calendar window.

The moat question for Harrow is whether a commercial distribution web in one medical specialty can function like a durable asset. The company sells through a dedicated eye-care field force that has roughly doubled during 2026, and through purchasing relationships with group purchasing organizations that reach ambulatory surgery centers and office based retina practices. IHEEZO exited the second quarter with 224 ordering accounts, up about a third year over year, and a reorder rate near eighty five percent over the trailing year. In a specialty where a single practice writes steady procedure volume, retention at that level behaves like an annuity on installed demand. The compounding heritage adds a second channel of a different texture: the ImprimisRx cash-pay shelf gives prescribers a fallback the branded pure plays lack, though its margin profile sits far below the branded one. The blended economics nonetheless matter, because the cash shelf keeps prescribers inside one purchasing relationship while the branded lines monetize the highest value uses.

VEVYE carries the growth burden and the clearest structural claim. The product rides a water free vehicle and enters a category where physicians treat inflammation as the foundation of disease progression, and it ended the second quarter with branded prescription share of roughly fifteen percent. The access architecture matters as much as the molecule. Formulary wins in April and again with a top-three national pharmacy benefit manager effective August 1 replaced blocked access with broad commercial coverage, while the April business rule amendments traded headline unit economics for net price improvement that held prescriptions growing through the switch. A dry eye asset that adds prescribers while raising realized price is compounding in the financial sense, and that dual motion is the core of the bull read. The bull case extends that arithmetic into next year by stacking the new formulary access, satisfied deductibles, and a prescriber base that no longer needs hand holding.

IHEEZO and TRIESENCE show how the same distribution engine prices replacement products into surgery. IHEEZO absorbed the April expiration of its Medicare pass-through status in ambulatory surgery centers, a change that wiped out that channel almost immediately, and still posted record unit demand with double digit growth in both directions. The explanation is channel migration toward in-office retina use, where the value proposition is strongest and reimbursement is durable, helped since July 1 by an estimated twenty five percent improvement in net price per unit. TRIESENCE, acquired calcified from Santen in late 2023, carries a permanent J-code and posted unit growth far above the market's rate, which supports the claim that ophthalmic anesthesia and surgical steroid demand responds to selling effort rather than to catalog presence. Unit prints of that shape during a pricing reset also argue that the volume lost when the ambulatory lane closed was replaceable rather than structural, and that distinction decides what the second half books.

TYRVAYA extends the same logic into a second dry eye modality, a nasal spray with a label profile management considers among the cleanest in the category, and BYOOVIZ plus the pipeline OPUVIZ build a retina biologics line on the same commercial rails. The MELT platform, acquired through the November 2025 purchase of Melt Pharmaceuticals, is the longer dated bet: an orally disintegrating sedation tablet aimed at the anesthesia coverage strain retina practices describe at their own advisory meetings. G-MELT holds a pre-NDA meeting grant and topline QUELL data lands in the fourth quarter. The portfolio is engineered so that each prescriber conversation carries more products per call, which is the mechanism by which a mid-cap house with a mid-sized field force competes against global manufacturers. Sedation economics complete the picture, because a tablet that removes anesthesia staffing strain addresses a cost the practices already pay through stipends, a budget line management characterizes as broad across retina surgery.

The reported numbers carry the tension the strategy creates. Second quarter revenue landed at $70.7 million, up sixty percent sequentially and eleven percent year over year, and VEVYE contributed a record $29.4 million of it with growth near forty percent sequentially. IHEEZO booked $15.6 million against $18.3 million a year earlier, and the gap reflects the ambulatory surgery center reimbursement expiration plus a previously forecast drawdown of channel inventory rather than a broken product. ImprimisRx meanwhile printed $14.6 million against $21.5 million in the prior year quarter, the lowest leg of the mix and the piece management links most directly to the deliberate portfolio migration. Three customers accounted for roughly ninety percent of receivables at midyear, a concentration worth tracking as the specialty pharmacy mix of VEVYE expands. Reporting discipline matters within that mix, since leadership concedes publicly that standalone trackers miss a growing slice of dispensing, an admission that raises the stakes on the audited lines.

Profitability is where the ramp claim faces its accounting. Adjusted EBITDA in the quarter arrived at roughly negative $1.2 million against positive $17 million a year earlier. The first half printed near negative $13.9 million. Gross margin held near seventy one percent of revenue in the quarter, down from seventy five percent a year earlier as mix shifted toward access program pricing. The selling and administrative line expanded to roughly $53 million for the quarter from $33 million a year earlier, the direct cost of doubled field teams and pre launch investment. Research development spend more than doubled year over year off a small base to fund the QUELL, Phase 3 TRIESENCE and G-MELT programs. The stated plan converts that spend into second-half leverage, and the guidance implies adjusted EBITDA for the second half in the range somewhere above ninety million on the full-year frame. Neither print includes the amortization load from acquired rights, one more gap between reported earnings and the adjusted measure the guide references. The gap cuts both ways, flattering the recovery if spend front runs revenue and punishing it if the reverse holds.

The balance between growth spend and coupon service defines the risk. Interest expense ran near $12 million in the first half, the cost of the notes issue now outstanding at a principal amount of $300 million. Operating cash flow consumed roughly $18.7 million over the half. Financing filled the hole with roughly $48 million of net proceeds from the March add-on notes sale, keeping the cash balance near $84 million at midyear. Management states that balance covers planned operations, capital spending and acquisitions for at least the next twelve months, and an undrawn $40 million revolver at Fifth Third sits behind it. Ratings of B3 and B minus across Moody's and Fitch frame the cost of that leverage, and the fair value of the notes at $306 million against a $292 million carrying figure shows the market lending at a discount to par. A fair value above carrying amount is the market's working verdict that near term default risk sits below the rating, and that verdict reprices quickly when conversion stalls.

Seasonality does some quiet work beneath these lines. Dry eye prescriptions rebound in the second and third quarters after deductible resets depress the first, and the company attributes part of the first-half EBITDA deficit to that rhythm. Working capital absorbed cash as receivables grew with the volume mix, while investing outflows carried milestone payments for acquired rights including the Samsung upfront and a $7 million VEVYE sales milestone. None of this is a crisis; all of it raises the stakes on the back-half conversion the guidance assumes. The read matters because frictions named publicly set the interpretation field for the next shortfall, and this management names them earlier and more precisely than most.

Management framed the second half as the quarter in which the heavy lifting ends and the serving begins, and the guidance arithmetic makes that framing falsifiable in a single report. First-half revenue totaled $114.9 million, so the full-year midpoint implies roughly $243 million across the second half, a pace more than double the first. The adjusted EBITDA ask is steeper still: the first half ran near negative $14 million. The implied second-half number lands somewhere near a hundred million on the full-year frame of $80 million to $100 million. Field expansion, pricing gains, formulary wins, an inventory drawdown now finished, and a biosimilar launch are the stated building blocks, and each carries a date attached to it. Skepticism about packaged inflections is warranted across small cap pharma, and the honest response is that the components here differ in kind, since pricing and inventory effects show up mechanically rather than through forecast.

Four committed events carry the outlook. The TYRVAYA acquisition closes in the second half with more than thirty million guided for 2027 revenue and a sales force adding experienced dry eye representatives at the closing. QUELL topline in the fourth quarter either adds clinical support to the in-office IHEEZO story or leaves it leaning only on commercial momentum. The TRIESENCE Phase 3 for postoperative inflammation and pain completes enrollment this year with data in early 2027, the study that expands or bounds that franchise's addressable claim. BYOOVIZ builds revenue through the second half after a July launch, with OPUVIZ behind it in 2027. Each lands inside the guidance window, which concentrates execution risk at a point rather than distributing it. A slip in any one of the four reopens the question the rest of the setup presumes answered, which is why the dates matter as much as the events themselves.

The mechanisms behind the ramp deserve scrutiny because the components differ in kind. VEVYE growth now rides pricing and coverage expansion more than share gains, since branded prescription share near fifteen percent already reflects a year of hyper growth, and the company states that increasingly the dispensing happens through partners whose volumes third-party trackers undercount. IHEEZO revenue accelerates mechanically in the third quarter as the July pricing improvement compounds with normalized channel levels and a full quarter of five unit packs. ImprimisRx recovers as rebuilt inventory reaches customers, with management targeting near full financial recovery by the fourth quarter. TYRVAYA contributes modestly in 2026 at best, so the headline number still depends on assets already in the bag. That dependence concentrates the year's verdict on products already shipped, where the open variable is the figure that books rather than the pipeline that gets built.

The risk register for the outlook is specific rather than generic. The January settlement with the California Board of Pharmacy surrendered the state's out-of-state compounding licenses in February, which removed a selling lane from the legacy channel, and any further state action compounds that loss. Receivables concentrate against three counterparties near ninety percent of the total. The Fifth Third revolver sits undrawn with maturity tied to the notes at the decade's end, and the coupon on $300 million of principal runs near twenty six million annually. Each of these is a known quantity; collectively they make the second half a timing problem as much as a growth problem. Timing claims of that kind are easier to verify than to model, because formulary placements, purchase orders and first fills leave auditable traces in receivables within weeks.

The counterargument deserves its plainest statement at the start of this section. The bear case holds that no specialty commercial presence justifies charging an effective enterprise multiple of sixteen or more for a company whose adjusted EBITDA ran negative in the first half, whose equity cushion compressed to roughly $15 million, and whose guidance demands a second-half swing that the company has repeatedly asked markets to take on faith. In this telling the Viatris transaction reads as buying revenue at a premium to conserve relevance in dry eye while the compounding franchise that funded the past decade shrinks by design and by settlement. The bull read and the bear read share the same inputs; only the conversion assumption differs. The disagreement deserves respect in both directions, because every factual input in this report, from the share count to the ratings, belongs to both sides of the argument.

The literature on this specific failure mode makes the downside quantifiable. First-half operating free cash flow ran near negative thirty one million before financing, combining the operating deficit with milestone outflows for acquired rights. If the second-half conversion disappoints by even a fifth, the fiscal year ends near $300 million of revenue with adjusted EBITDA far below the guide, the cash balance heads toward a ten-digit squeeze at the coupon's run rate near twenty six million annually, and the equity story becomes a refinancing story priced against B3 credit ratings. A delay and a shortfall carry different endings, since a delay drains cash slowly across statements while a shortfall breaks the underwriting inside a single period. The notes' market value already sits above the carrying figure, which signals how bond investors price that contingency.

Concentration and regulatory geography create the structural legs of the downside. Three counterparties carry roughly ninety percent of receivables, so any specialty pharmacy disruption transmits fast through collections. The California settlement surrendered the out-of-state compounding licenses in February, and the filing language warns that further state actions carry cumulative material effect. Remediation of the New Jersey outsourcing facility continues under voluntary FDA communication following the 2024 inspection findings, an arrangement that stays cooperative by definition only until it does not. None of these is a current earnings problem; each is an option the environment holds against the franchise. Remediation quality interacts directly with the branded pivot, since any forced pause at the outsourcing facility would leave the very prescribers the migration programs courted waiting on the legacy alternative.

The bull side of the same ledger is not aspirational but contractual. The TYRVAYA purchase closes on cash the company already holds, adds guided revenue above its incremental cost from 2027, and brings reps the seller already trained in the same category. VEVYE coverage expansion took effect with the August 1 formulary change, and its commercial lives began flowing the same month. IHEEZO reprice landed July 1, and the trial calendar prints on schedule. The scenario spread is therefore transparent in one respect and treacherous in another: the base case asks for ordinary execution, while the bear case asks only that execution stay a few weeks slower than the coupon. That spread narrows the premium in the entire setup to a question of pacing inside two reported quarters. A timely closing of the Viatris purchase completes the last building block, and the incoming representatives arrive already trained, which shortens the ramp the guide assumes.

The framework here evaluates Harrow as a levered claim on second-half conversion rather than as a sum of catalog parts. At the mid September close near $34 the market carried the equity cap near $1.28 billion. That figure rests on a share base of roughly 37.5 million shares. Adding net debt of $208 million at midyear lifts the enterprise value near $1.49 billion. Measured against the guidance midpoint, the quote prices about four times forward sales. It also prices about sixteen times the midpoint of guided adjusted EBITDA, a rate the market reserves for companies it believes already cleared their inflection. For a house whose leading products carry exclusivity into the next decade, that rate reads as respect and doubt at once, and separating the two is the working question.

The bear scenario prices failure of that belief. A shortfall that leaves adjusted EBITDA near $45 million with momentum stalling merits the discount a B3 credit earns absent proof, roughly ten times. The resulting enterprise value sits near $450 million, and $208 million of net debt consumes nearly half of it. Equity falls near $242 million, which on the current share count prints about $6 per share. A bear case at that depth is a credit narrative and not a growth narrative, and the bond market's own marks suggest participants treat that branch as conditional rather than remote. One notch worse, where pricing concessions arrive alongside the shortfall, compresses the same arithmetic further and turns the equity into an option on refinancing rather than on recovery.

The base case takes the guidance midpoint of $90 million adjusted. Applying sixteen times, the rate profitable ophthalmic houses carry once inflection is demonstrated, yields an enterprise value near $1.44 billion. Netting the $208 million of net debt leaves equity near $1.23 billion. On 37.5 million shares that prints about $33 per share, just under the current quote. The market already concedes the guided outcome, which is the frame's most useful property: at this level the holder buys execution verification instead of faith. Verification of that kind needs no model beyond the quarterly statements, because the revenue line either lands near the required build or the frame resolves against the holder.

The bull case takes the top of the frame, $100 million adjusted EBITDA, at seventeen and three fifths times. The resulting enterprise value near $1.76 billion nets to equity near $1.55 billion. Per share that lands within a rounding error of $41, about a fifth above the current quote. The bridge beyond this year explains why the skew likely favors that branch: management has told holders the company targets a $250 million revenue quarter by the end of 2027. A portfolio that converts at even half that goal, near $500 million of annual revenue at a thirty percent margin, carries a fourteen times multiple to equity near $52 per share. The conclusion from the frame is straightforward: the present quote is a base case price with a bull option attached and bear risk carried in the bond side of the balance sheet, so the payoff to verification work is asymmetric. Holders of the bull branch own it precisely until conversion evidence slips, at which point the notes' seniority decides outcomes, an arrangement the market prices efficiently and without sentiment.

The judgment this report reaches is that Harrow at the mid September quote is a fairly priced claim on a single, well defined test that resolves by early next year. The company built a franchise breadth in one specialty that took a decade to assemble, financed it with a coupon just under nine percent on a principal of $300 million, and then scheduled nearly every proof point of the strategy into one calendar window: the TYRVAYA closing, the QUELL readout, the first clean IHEEZO economics, and the pharmacy benefit coverage that took effect in August. The valuation work above shows the market paying exactly the guided base case, which means verification is cheap and disappointment is not.

The decision framework that follows for a reader of this report is evidence based rather than calendar based. The third-quarter report carries more informational weight than any prior release in this cycle, because it either books the double-digit sequential build the guidance requires or reveals that demand signals were inflated by the very channel undercounting management describes. The same report discloses whether the ImprimisRx recovery reached the pace that near full recovery by year end requires. Those two disclosures together settle most of the disagreement between the base case near $33 per share and the bear near single digits. The third variable, realized pricing, shows up in gross margin rather than volume, and the July repricing front runs the exact quarter that tests it.

The asymmetric part of the frame is worth stating as the closing judgment. Assets of that kind reward the reader who anchors on disclosed evidence rather than on the sentiment cycles that dominate the coverage. Durable specialty franchises built through acquisition by a founder led operator tend to re rate in stages, and the staged history here, from compounding outsider to owner of a branded dry eye, anesthesia and retina shelf, is exactly that pattern at work. What separates the stages from a value trap is cash conversion, and cash conversion is precisely the variable the second half either demonstrates or does not. The bear case requires only slower execution; the bull case requires only delivered execution. Facts, not sentiment, decide between them. The operator's record weighs on that judgment, since the same leadership converted a compounding service into a branded shelf without a rights issue to the common, absorbing margin consequences along the way.

On balance the report frames the stock as priced at approximately fair value with the verification catalysts inside a single quarter, and it treats the balance sheet, not the demand line, as the binding constraint if that verification slips. The five-year plan the company outlines in March 2027, with the MELT platform and the retina expansion, is the following act. The current act closes sooner, in a quarterly filing whose numbers either service the paper or renegotiate the terms of belief. Quotes that suspend judgment on both sides of that line tend to misprice symmetrically, which is the quiet argument for letting the audited figures, not the commentary around them, set the position.